Nivolumab shows signs of superior response rate compared to standard chemo in advanced melanoma

Bookmark and Share
Published: 29 Sep 2014
Views: 2233
Dr Jeffrey Weber - Moffitt Cancer Center, Tampa, USA

At a press conference at ESMO 2014, Dr Weber presents the results of a phase III trial which looked at the use of nivolumab versus investigator's choice chemotherapy in advanced melanoma after anti-CTLA-4 therapy.

Read the news story for more.